Oncotarget

Research Papers:

The mitochondrial carrier SLC25A10 regulates cancer cell growth

Xiaoshan Zhou, João A. Paredes, Shuba Krishnan, Sophie Curbo and Anna Karlsson _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:9271-9283. https://doi.org/10.18632/oncotarget.3375

Metrics: PDF 1101 views  |   HTML 1392 views  |   ?  


Abstract

Xiaoshan Zhou, João A. Paredes, Shuba Krishnan, Sophie Curbo, Anna Karlsson

Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden

Correspondence to:

Anna Karlsson, e-mail: anna.karlsson@ki.se

Keywords: oxidative stress, redox homeostasis, ROS, SLC25A10

Received: December 18, 2014     Accepted: February 11, 2015     Published: March 09, 2015

ABSTRACT

Dysregulation of cell metabolism is critical for the growth properties of cancer cells. The purpose of this study was to understand the role of substrate transport across the mitochondrial membrane to sustain the metabolic shift and redox defense in cancer cells. Mitochondrial carrier SLC25A10 is up-regulated in a variety of tumors and is involved in regulating intracellular levels of reactive oxygen species. We show that knockdown of SLC25A10 in A549 cells changed the growth properties to a less malignant phenotype and casued increased glutamine dependency and sensitivity to oxidative stress. The metabolic alteration was linked to an energy metabolic shift from glycolysis to mitochondrial oxidative phosphorylation illustrated by increased expression of glutamate dehydrogenase, decreased expression of lactate dehydrogenase due to down-regulation of hypoxia inducible factor 1α. We identified effects on NADPH production linked to the growth changes observed in SLC25A10 knockdown cells, demonstrated by decreased NADPH production in cells deprived of glutamine. The contribution of SLC25A10 to reprogram cell metabolism and to regulate cell growth suggests SLC25A10 as a novel target for anti-cancer strategies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3375